# CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

> **NCT07366112** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 158 (estimated)

## Conditions studied

- Hormone Receptor-Positive Breast Cancer
- High-risk Breast Cancer
- Early-Stage Breast Cancer
- HER2-negative Breast Cancer
- ctDNA Monitoring

## Interventions

- **DRUG:** CDK4/6 inhibitor with endocrine therapy

## Key facts

- **NCT ID:** NCT07366112
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07366112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07366112, "CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07366112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*